<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485106</url>
  </required_header>
  <id_info>
    <org_study_id>SDS-SAH-001</org_study_id>
    <nct_id>NCT02485106</nct_id>
  </id_info>
  <brief_title>Rifaximin Use in Severe Alcoholic Hepatitis</brief_title>
  <official_title>Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Vincent's Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Vincent's Hospital, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate the effect of decontamination by rifaximin in severe
      alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be
      randomly allocated to rifaximin group or control group.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>6-month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Severe Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Rifaximin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corticosteroid or Pentoxifylline for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>400mg three times per day for 28 days</description>
    <arm_group_label>Rifaximin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroid or pentoxifylline</intervention_name>
    <description>Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days</description>
    <arm_group_label>Rifaximin group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heavy alcohol drinking within 3 months (Over 40 g/day)

          -  Maddrey's discriminant function ≥ 32

          -  AST/ALT ration ≥ 2

          -  Bilirubin level ≥ 5mg/dL

          -  Any one of the following additional criteria : hepatic encephalopathy, enlarged,
             tender liver, or peripheral leucocytosis

          -  Age : 19-75

          -  Jaundice within 3 months

        Exclusion Criteria:

          -  Other causes of chronic liver disease (HBV, HCV, or autoimmune hepatitis)

          -  Antibiotics or probiotics use within 8 weeks

          -  Drug induced hepatotoxicity

          -  Acute viral hepatitis (HAV or HEV)

          -  Hepatic abscess or cholagitis

          -  Hepatocellular carcinoma of modified UICC stage II, III or IV

          -  Malignant tumor other than HCC

          -  Pregnancy

          -  Severe chronic extrahepatic disease

          -  Type I hepatorenal syndrome

          -  Hepatic encephalopathy grade II or IV

          -  Severe infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Do Seon Song</last_name>
    <phone>82-31-249-8204</phone>
    <email>dsman@catholic.ac.kr</email>
  </overall_contact>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Vincent's Hospital, Korea</investigator_affiliation>
    <investigator_full_name>Do Seon Song</investigator_full_name>
    <investigator_title>Clinical assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

